Equity Profile

CTNM

Contineum Therapeutics, Inc.

Health CarePharmaceuticals$504.3M

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Contineum Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies to address unmet medical needs....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CTNM Q2-2026 Earnings Preview

Context

Company Snapshot

Contineum Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies to address unmet medical needs. With a market cap of $1 billion, it operates in the health care sector, which is increasingly important as the demand for effective treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1.76%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In Q1-2026, Contineum reported an EPS of -$0.39, beating analyst expectations by nearly 30%. The stock reacted positively, gaining 1.70% the following day.

Management Promises & Guidance

Focus on advancing key drug candidates in the pipeline.
Commitment to improving operational efficiency.
Plans to enhance investor communication and transparency.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown some positive surprises in the past, but there is uncertainty about future revenue growth.

Bull Case

If Contineum can continue to beat EPS estimates and demonstrate strong revenue growth, it could signal a turnaround and attract more investor interest.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of stagnation in its product pipeline, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

EPS is a critical measure of profitability, and a significant deviation from expectations could impact investor sentiment.

How much has the company invested in R&D this quarter?

Investments in R&D are crucial for future growth, and clarity on this figure will indicate the company's commitment to innovation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Contineum's potential for a significant turnaround due to its recent positive EPS surprises and ongoing R&D efforts.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, indicating improving performance.

Options pricing suggests a much larger move than historical averages, hinting at potential volatility that the market may not be fully accounting for.

Key Risk

If R&D spending shows a significant increase, it could indicate strong future growth potential, challenging current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Contineum can maintain its momentum in profitability and innovation.

Bull Confirmed If

An EPS of -$0.30 or better would confirm the bull case, indicating improved profitability.

Bear Confirmed If

An EPS worse than -$0.55 would confirm the bear case, suggesting ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±46.7%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±25.8% while CTNM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.3%

30d HV

58.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 27 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 27 faded and 14 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.6%, with a raw directional average of +3.0% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Contineum beats expectations, history suggests the stock could rise by about 3.0%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may see little movement or a slight decline.

Miss

If the company misses earnings expectations, history suggests a potential decline of around 0.1%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on key drug candidates in the pipeline.
2Details on R&D spending and its impact on future growth.
3Management's outlook on market conditions and competition.
4Insights into sales performance and customer feedback.
5Any changes in strategic partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Contineum Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies to address unmet medical needs....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CTNM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1.76%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In Q1-2026, Contineum reported an EPS of -$0.39, beating analyst expectations by nearly 30%. The stock reacted positively, gaining 1.70% the following day.

Management Promises & Guidance

Focus on advancing key drug candidates in the pipeline.
Commitment to improving operational efficiency.
Plans to enhance investor communication and transparency.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown some positive surprises in the past, but there is uncertainty about future revenue growth.

Bull Case

If Contineum can continue to beat EPS estimates and demonstrate strong revenue growth, it could signal a turnaround and attract more investor interest.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of stagnation in its product pipeline, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

EPS is a critical measure of profitability, and a significant deviation from expectations could impact investor sentiment.

How much has the company invested in R&D this quarter?

Investments in R&D are crucial for future growth, and clarity on this figure will indicate the company's commitment to innovation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Contineum's potential for a significant turnaround due to its recent positive EPS surprises and ongoing R&D efforts.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, indicating improving performance.

Options pricing suggests a much larger move than historical averages, hinting at potential volatility that the market may not be fully accounting for.

Key Risk

If R&D spending shows a significant increase, it could indicate strong future growth potential, challenging current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Contineum can maintain its momentum in profitability and innovation.

Bull Confirmed If

An EPS of -$0.30 or better would confirm the bull case, indicating improved profitability.

Bear Confirmed If

An EPS worse than -$0.55 would confirm the bear case, suggesting ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±46.7%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±25.8% while CTNM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.3%

30d HV

58.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 27 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Contineum beats expectations, history suggests the stock could rise by about 3.0%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may see little movement or a slight decline.

Miss

If the company misses earnings expectations, history suggests a potential decline of around 0.1%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on key drug candidates in the pipeline.
2Details on R&D spending and its impact on future growth.
3Management's outlook on market conditions and competition.
4Insights into sales performance and customer feedback.
5Any changes in strategic partnerships or collaborations.